STOCK TITAN

Sage Therapeutic Stock Price, News & Analysis

SAGE NASDAQ

Company Description

Overview

Sage Therapeutics is a clinical-stage biopharmaceutical company with a dedicated focus on advancing brain health medicines. With a primary commitment to tackling challenging CNS disorders, the company harnesses a deep scientific understanding to drive innovation in the treatment of depression, neurology, and neuropsychiatry. By leveraging robust clinical research and a pipeline of potentially transformative therapies, Sage Therapeutics aims to address unmet medical needs with a focus on safety, efficacy, and scientific excellence.

Business Model and Core Focus

The company operates within the biopharmaceutical sector, primarily generating value through the discovery and development of novel medicines targeted at central nervous system indications. Its business model revolves around translating groundbreaking neuroscience research into clinical-stage drug candidates that address both common and rare CNS disorders. Central to its strategy is the purposeful targeting of two critical receptor systems—GABA and NMDA—which have been linked to key pathways in mood regulation and cognitive function. This dual receptor strategy positions Sage Therapeutics as a focal point for innovative drug development, addressing patient populations that have been historically underserved.

Scientific Excellence and Research Initiatives

Sage Therapeutics distinguishes itself with a solid scientific foundation built on years of rigorous research and a portfolio of compounds generated from its robust chemistry platform. The company’s research efforts are characterized by:

  • Innovative Chemistry: The creation of new compounds that interact with CNS receptors, aiming to modulate brain activity in a therapeutic manner.
  • Targeted Pharmacology: Focus on GABA and NMDA receptors provides a strategic and scientific rationale for addressing disorders such as depression and seizure-related conditions.
  • Robust Clinical Foundations: Extensive preclinical activity and clinical development programs attest to the company’s commitment to advancing promising drug candidates through the necessary stages of evaluation.

Key Programs and Pipeline

Sage Therapeutics has structured its development pipeline with a mix of early and mid-stage clinical candidates targeting specific CNS disorders. Among its noteworthy programs are therapies aimed at addressing postpartum depression and rare epileptic conditions, as well as treatments targeting cognitive impairment. The company has developed treatment modalities that include both oral and injectable formulations, each designed to meet distinct clinical needs while adhering to rigorous safety and efficacy standards. This balanced pipeline not only underscores its scientific versatility but also reinforces its strategic focus on meaningful clinical outcomes.

Market Position and Competitive Landscape

Positioned within a highly competitive sphere of neuroscience-focused biopharma companies, Sage Therapeutics harnesses its specialized research and a diverse drug portfolio to effectively address complex CNS disorders. The company’s approach, which integrates strong basic science with advanced clinical development, enables it to navigate an industry marked by stringent regulatory standards and competitive innovation. Sage Therapeutics differentiates itself by focusing on creating medicines that fulfill critical therapeutic gaps, particularly in conditions where conventional treatments have been limited or ineffective.

Expertise, Partnerships, and Collaborative Approach

The company is supported by a world-class team comprising founders, advisors, research and development leaders, and industry experts. This collective expertise fosters an environment of continuous innovation and strategic collaboration. By working with academic institutions, research organizations, and clinical experts, Sage Therapeutics not only accelerates the development of its therapeutic candidates but also reinforces its credibility through diverse external partnerships. This collaborative framework exemplifies the company’s commitment to scientific rigor and transparency, which are crucial in the evolving fields of neuroscience and biopharmaceutical innovation.

Commitment to Science and Innovation

At its core, Sage Therapeutics is driven by the mission to improve life for patients suffering from serious CNS disorders through pioneering drug development. Its integrated approach combines cutting-edge science, a robust pipeline of clinical candidates, and strategic partnerships to generate potential therapies with meaningful clinical impact. The company’s careful navigation of the research and clinical landscape—marked by in-depth scientific inquiry and adherence to regulatory standards—shows a commitment to both innovation and the highest levels of medical and research excellence.

Conclusion

In summary, Sage Therapeutics represents a focused and scientifically driven approach to addressing central nervous system disorders. With its deep research foundation, multi-faceted clinical programs, and a strategic vision anchored in targeting GABA and NMDA receptors, the company has positioned itself as an expert in the biotech and pharmaceutical arena. Its comprehensive and collaborative methodology serves as a testament to the critical role of rigorous scientific inquiry in developing meaningful, life-improving therapies for some of the most challenging brain health conditions.

Stock Performance

$—
0.00%
0.00
Last updated:
-75.85 %
Performance 1 year
$456.8M
Market Cap
61.5M
Shares outstanding

SEC Filings

No SEC filings available for Sage Therapeutic.

Financial Highlights

$41,243,000
Revenue (TTM)
-$400,666,000
Net Income (TTM)
-$6.59
Diluted EPS (TTM)
-$267,194,000
Operating Cash Flow
-971.48%
Net Profit Margin
-1,048.35%
Oper. Profit Margin

Upcoming Events

April 29, 2025
Q1 2025 earnings call

Frequently Asked Questions

What is the current stock price of Sage Therapeutic (SAGE)?

The current stock price of Sage Therapeutic (SAGE) is $7.79 as of April 25, 2025.

What is the market cap of Sage Therapeutic (SAGE)?

The market cap of Sage Therapeutic (SAGE) is approximately 456.8M.

What is the revenue (TTM) of Sage Therapeutic (SAGE) stock?

The trailing twelve months (TTM) revenue of Sage Therapeutic (SAGE) is $41,243,000.

What is the net income of Sage Therapeutic (SAGE)?

The trailing twelve months (TTM) net income of Sage Therapeutic (SAGE) is -$400,666,000.

What is the earnings per share (EPS) of Sage Therapeutic (SAGE)?

The diluted earnings per share (EPS) of Sage Therapeutic (SAGE) is -$6.59 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Sage Therapeutic (SAGE)?

The operating cash flow of Sage Therapeutic (SAGE) is -$267,194,000.

What is the profit margin of Sage Therapeutic (SAGE)?

The net profit margin of Sage Therapeutic (SAGE) is -971.48%.

What is the operating margin of Sage Therapeutic (SAGE)?

The operating profit margin of Sage Therapeutic (SAGE) is -1,048.35%.

What is the current ratio of Sage Therapeutic (SAGE)?

The current ratio of Sage Therapeutic (SAGE) is 7.42, indicating the company's ability to pay short-term obligations.

What is the operating income of Sage Therapeutic (SAGE)?

The operating income of Sage Therapeutic (SAGE) is -$432,370,000.

What is the primary focus of Sage Therapeutics?

Sage Therapeutics is dedicated to developing innovative medicines to treat central nervous system disorders, focusing on conditions such as depression, neurology, and neuropsychiatry.

Which receptor systems are targeted by the company?

The company strategically targets the GABA and NMDA receptor systems, which are crucial in the modulation of brain function and linked to various CNS disorders.

How does Sage Therapeutics drive its drug development?

Sage Therapeutics leverages a robust chemistry platform and extensive clinical research, working with world-class experts and strategic partnerships to move promising drug candidates through clinical development.

What therapeutic areas are included in the company’s pipeline?

The pipeline spans several therapeutic areas, including treatments for postpartum depression, epilepsy-related conditions, and cognitive impairments, reflecting its broad neuroscience focus.

How does the company position itself within the competitive landscape?

By integrating rigorous scientific research with advanced clinical development, Sage Therapeutics differentiates itself as a focused biopharmaceutical innovator addressing critical gaps in CNS disorder treatments.

What role do strategic partnerships play at Sage Therapeutics?

Collaborative efforts with academic institutions, clinical experts, and research organizations help enhance the company’s research capabilities and accelerate the development of its therapeutic candidates.

Can you describe the company’s approach to research and development?

The approach is anchored in deep scientific inquiry and a commitment to innovation, combining robust preclinical and clinical research to create therapies that address major unmet medical needs in brain health.

How does Sage Therapeutics ensure scientific credibility?

The company builds its credibility through a world-class team of experts, rigorous clinical studies, and a sustained focus on targeting key CNS receptor systems, demonstrating both expertise and strategic precision in drug development.